Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

Surrey
21 November 2014 09:10


Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818 010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+44 1494 818 010

Testimonials
I've been associated with Zenopa for few months now and since registering I've always found the entire team to be professional and helpful in choosing my new sales position with a private sector compa...
Tushar, 2012

Novartis reports positive data from COPD drug trials

5 April 2012 00:00 in Pharmaceutical Company Product News


Novartis has reported positive clinical trial data from three studies of QVA149, its innovative new therapy for chronic obstructive pulmonary disease (COPD).

Results have emerged from Shine, Bright and Enlighten, the first three trials in the Ignite study programme, which aims to provide detailed data on the safety and efficacy of the dual-mode bronchodilator.

The drug was able to meet its primary endpoints in all three of the studies after demonstrating superior performance to placebo and an alternative therapy option.

A further seven trials will be completed as part of the Ignite programme, with the data set to support regulatory filings for the compound later this year.

Tim Wright, head of development at Novartis Pharmaceuticals, said: "Meeting the primary endpoints ... signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio."

Last month, the company received a provisional recommendation from the National Institute for Health and Clinical Excellence for its multiple sclerosis therapy Gilenya.ADNFCR-8000103-ID-801334650-ADNFCR

Other news stories from 05/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd